Human Mesenchymal Stem Cell (hMSC) Donor Potency Selection for the "First in Cystic Fibrosis" Phase I Clinical Trial (CEASE-CF)

• Main Authors: Tracey L. Bonfield (Author), Morgan T. Sutton (Author), David R. Fletcher (Author), Jane Reese-Koc (Author), Erica A. Roesch (Author), Hillard M. Lazarus (Author), James F. Chmiel (Author), Arnold I. Caplan (Author)
• Format: Book
• Published: MDPI AG, 2023-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Human Mesenchymal Stem Cell (hMSC) immunotherapy has been shown to provide both anti-inflammatory and anti-microbial effectiveness in a variety of diseases. The clinical potency of hMSCs is based upon an initial direct hMSC effect on the pro-inflammatory and anti-microbial pathophysiology as well as...